-
GSK’s Acquisition of Aiolos Bio Bolsters Respiratory Medicine Portfolio with AIO-001
•
UK pharmaceutical giant GSK plc (LON: GSK) has announced a deal to acquire Aiolos Bio, a US/UK-based biotechnology company focused on the development of the respiratory antibody AIO-001. Aiolos was established in October 2023 when it secured the rights to develop AIO-001 outside of Greater China from Jiangsu Hengrui Pharmaceuticals…
-
WuXi AppTec Expands Peptide Manufacturing Capacity with Two New Plants in China
•
WuXi AppTec (HKG: 2359, SHA: 603259), a leading China-based Contract Research, Development, and Manufacturing Organization (CRDMO), has announced the commissioning of two new peptide manufacturing plants. One plant is located at its existing facility in Changzhou, and the other is a new site in Taixing. This expansion adds 32,000 liters…
-
Sino Medical Sciences’ HT Supreme Drug-Eluting Stent System Gains Market Approval in Bangladesh
•
Sino Medical Sciences Technology Inc., (SHA: 688108), a Chinese medical device company, has announced that it has received market approval in Bangladesh for its HT Supreme drug-eluting stent system. The system is designed to improve the diameter of the coronary artery lumen in patients with symptomatic heart disease caused by…
-
Novartis’s Cosentyx Secures Additional Indication for Psoriatic Arthritis in China
•
Swiss pharmaceutical giant Novartis (SWX: NOVN) has announced that its drug Cosentyx (secukinumab), which targets IL-17A, has received an additional indication approval from the National Medical Products Administration (NMPA) in China. The drug is now approved for the treatment of active psoriatic arthritis (PsA), adding to its existing indications in…
-
Pfizer and Genmab’s Tivdak Earns Priority Review from FDA for Full Registration
•
The US Food and Drug Administration (FDA) has accepted for priority review a filing from Pfizer (NYSE: PFE) and Genmab (NASDAQ: GMAB) for the full registration of their antibody-drug conjugate (ADC) Tivdak (tisotumab vedotin). Tivdak currently holds an accelerated approval from 2021 for the treatment of recurrent or metastatic cervical…
-
International Society for Cell & Gene Therapy Comments on FDA’s CAR-T Investigation
•
The International Society for Cell & Gene Therapy (ISCT) has published a statement addressing the US Food & Drug Administration’s (FDA) investigation into a potential link between T-cell malignancies and CAR-T cell therapies. The FDA launched the inquiry in November following 20 reported cases of patients developing these malignancies after…
-
Meizhong Jiahe Medical Debuts on Hong Kong Stock Exchange Below IPO Price
•
China-based Meizhong Jiahe Medical Science & Technology Development Co., Ltd has completed its initial public offering (IPO) on the Hong Kong Stock Exchange, with shares priced at HKD 14.28 per share. The stock opened trading at HKD 9.8 per share and, as of the noon close, had risen to HKD…
-
AbbVie Launches Continuous Infusion Therapy for Advanced Parkinson’s Disease in EU
•
AbbVie (NYSE: ABBV) has announced the launch of its dopamine replacement therapy, Produodopa (foslevodopa + foscarbidopa), in the European Union (EU) for the treatment of advanced Parkinson’s disease (PD). The therapy is indicated for patients experiencing severe motor fluctuations, hyperkinesia, or dyskinesia, and when other treatments fail to adequately control…
